NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes
– NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform – Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected in Q1 2023 – Phase 1 trial with SEFA-1024 (being developed for the treatment of severe hypertriglyceridemia) completed in Q4 2022 […]
